Navigation Links
Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
Date:10/30/2007

------------------------------------------------------

-------------------------------------------------------------------------

Stock based compensation for the third quarter of 2007 was $38,909 compared to $34,671 for the third quarter of 2006. In the third quarters of 2007 and 2006, we incurred stock based compensation associated with the vesting of previously granted options.

YEAR TO DATE RESULTS OF OPERATIONS

(for the nine months ended September 30, 2007 and 2006)

Net loss for the nine month period ending September 30, 2007 was $11,556,714 compared to $9,407,419 for the nine month period ending September 30, 2006.

Research and Development Expenses ("R&D")

2007 2006

$ $

-------------------------------------------------------------------------

Manufacturing and related process

development expenses 3,546,732 2,751,207

Clinical trial expenses 2,983,688 1,920,467

Pre-clinical trial and research

collaboration expenses 731,445 691,553

Other R&D expenses 1,553,390 1,219,460

-------------------------------------------------------------------------

Research and development expenses 8,815,255 6,582,687

-------------------------------------------------------------------------

-------------------------------------------------------------------------

For the nine month period ending September 30, 2007, R&D increased to $8,815,255 compared to $6,582,687 for 2006. The increase in R&D was due to the following:

Manufacturing & Related Process Development ("M&P")

2007 2006


'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  NeuroLifeSciences ... of mazindol in children with attention deficit/hyperactivity disorder published ... 2014 . The paper, titled "Pilot ... deficit/hyperactivity disorder" ( Konofal et al, Drug ... 2014 ) shows that mazindol might be an ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
(Date:12/22/2014)... 2014  ( www.competitivehealth.com ) — Competitive Health is ... review and advocacy service, has signed an agreement to ... discount health services marketplace. 63% of Americans ... they expected to pay. As part of an ongoing ... Savings is pleased to offer medical bill review and ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced a new ... network of more than 20 contributing fertility practices ... access to a national pool of frozen donor ... of Memphis is the only fertility clinic in the ... Dr. William Kutteh , director of Fertility Associates of ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
... Program Called ... ... GEN),announced today a new pre-clinical antibody program called HuMax-CD32b(TM).,This fully ... and hematological tumors. HuMax-CD32b may have therapeutic potential,in the treatment ...
... of gallons of hazardous waste resulting from the nations ... southeastern Washington state called Hanford. Beneath this desert ... of thousands of tons of chemicals are captured within ... complex subsurface flow paths. These paths create uncertainties ...
... 3 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), China,s premier provider ... that it has promoted Mr. Edward Hu from Executive,Vice ... to joining WuXi PharmaTech in August 2007, Mr. Hu ... Tanox, Inc., a NASDAQ listed,company later acquired by Genentech, ...
Cached Biology Technology:Genmab Announces HuMax-CD32b Pre-Clinical Program 2Genmab Announces HuMax-CD32b Pre-Clinical Program 3Where does stored nuclear waste go? 2WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO 2
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/10/2014)... California , December 9, 2014 ... with ITN,s BCARD Platform   ... cloud-based enterprise meeting scheduling solutions for business-to-business (B2B) ... the world leader in mobile near-field communication (NFC), ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... Pittsburgh of UPMC have identified a potential target ... trachomatis, the most prevalent sexually transmitted bacterial infection ... Toni Darville, MD, chief of the Division of ... strain of Chlamydia that, when investigated in an ...
... artificial heart-valve replacements face several repeat operations as they ... and must be traded for bigger ones. Researchers at ... growing valves created in the lab from a patients ... published September 11, they describe making pulmonary valves through ...
... critical to how successful treatment can be. Therefore, the ... field, where every small step is of great importance. ... Cellular Proteomics, Uppsala University researchers describe a technique that the ... bodys cells and tissues, and our knowledge of the human ...
Cached Biology News:Study by Pittsburgh researchers identifies possible vaccine target for chlamydia 2A step toward tissue-engineered heart structures for children 2
...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
... DNase I Amplification Grade ... DNA to oligodeoxyribonucleotides. The ... units/mg. DNAse I Amplification ... and tested for absence ...
Biology Products: